Moberg Pharma: Positive surprises

Research Note

2019-10-01

08:04

Management once again demonstrates its commitment to building shareholder value by signing yet another significant licensing agreement for MOB-015. The deal with Taisho providing cash, making it possible to raise the shareholder payment to SEK 46.50 from the previously announced interval of SEK 43-45, but also to repay outstanding debt.

KP

Klas Palin

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.